Evaluation of the oral direct factor Xa inhibitor-betrixaban

Expert Opinion on Investigational Drugs

Volumn 22, Issue 11, 2013, Pages 1465-1472

  Palladino, Michael ^a   Merli, Geno ^a   Thomson, Lynda ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulants; Factor Xa inhibitors; Venous thromboembolism

Indexed keywords

ANTIDOTE; ANTITHROMBIN III; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; CYTOCHROME P450; DABIGATRAN; DIGOXIN; ENOXAPARIN; KETOCONAZOLE; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; PROTHROMBIN; PRT 064445; PRT 4445; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOEMBOLISM; URINARY EXCRETION;

ANIMALS; ANTICOAGULANTS; BENZAMIDES; FACTOR XA; HUMANS; PYRIDINES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84885772245     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.825605     Document Type: Article

References (15)

1. Weitz JI. Factor xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(SUPPL. 2):S5-S12 .. A review article focusing on the new oral anticoagulants and their most advanced stages of development. A valuable article to understand the comparisons of studies and pharmacologic/kinetic of the new agents.
2. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22 .. A detailed review of the pharmacokinetic and pharmacologic profiles related to the new oral anticoagulants.
3. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86 . A randomized, double blind trial comparing rivaroxaban to enoxaparin for VTE prophylaxis post TKA. This was one trial responsible for FDA approval for post-operative VTE prophylaxis.
4. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-7; e1 . A randomized, double blind trial of over 14,000 patients comparing rivaroxaban to warfarin for the prevention of stroke in non-valvular A-fib. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism.
5. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510 . We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT.
6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92 . A randomized, double-blind trial, comparing apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in over 18,000 patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
7. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,Ndimethylcarbamimidoyl) benzamido)-5- methoxybenz amide, a highly potent, selective, and orally efficacious factor xa inhibitor. Bioorg Med Chem Lett 2009;19(8):2179-85 . A detailed description of the discovery of betrixaban. The discovery of compound 1 is described as well as the modification to compound 1 to the currently active compound.
8. Morganroth J, Gretler DD, Hollenbach SJ, et al. Absence of QTc prolongation with betrixaban: A randomized, double-blind, placeboand positive-controlled thorough ECG study. Expert Opin Pharmacother 2013;14(1):5-13 .. A paper evaluating the effects of the anticoagulant betrixaban on individual heart rate-corrected QT. Betrixaban was used at both low and high doses for analysis.
9. Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a phase 2, randomized, dose-ranging study (explore-xa). Eur Heart J 2013; doi: 10.1093/eurheartj/ eht039 .. A safety and tolerability study of oral betrixaban at doses of 40, 60 and 80 mg once a day compared with dose-adjusted warfarin in patients with non-valvular atrial fibrillation or atrial flutter.
10. Turpie AG, Hull RD, Schellong SM, et al. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: Results from the EXCLAIM study. Stroke 2013;44(1):249-51 . Thromboembolism in Acutely lll Medical Patients With Prolonged Immobilization (EXCLAIM) study investigated extended-duration thromboprophylaxis with enoxaparin, compared with placebo following standard-duration enoxaparin, in ischemic stroke patients.
11. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101(1):68-76 .. A randomized study of betrixaban?s safety and efficacy of post-operative VTE prophylaxis compared to enoxaparin 30mg sub-Q Q12H.
12. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341(11):793-800 . A double-blind study where patients received 40 mg of enoxaparin, 20 mg of enoxaparin, or placebo subcutaneously once daily for 6 to 14 days. The primary outcome was VTE between days 1 and 14, defined as deep-vein thrombosis detected by bilateral venography (or duplex ultrasonography) between days 6 and 14 (or earlier if clinically indicated) or documented pulmonary embolism. The duration of follow-up was three months.
13. Heit JA, Melton LJ III, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001;76(11):1102-10
14. Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011;31(4):407-16 . A study to determine whether oral rivaroxaban is non-inferior to standard-duration (approximately 10 days) subcutaneous enoxaparin for the prevention of VTE in acutely ill medical patients, and whether extended-duration (approximately 5 weeks) rivaroxaban is superior to standard-duration enoxaparin.
15. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor xa. Nat Med 2013;19(4):446-51